Heidelberg Pharma AG is a biopharmaceutical company focused on developing novel drugs for oncology using its proprietary Antibody Drug Conjugate (ADC) technologies. The company is pioneering the use of the toxin Amanitin in cancer therapies.
Focus Areas
Notable Investments
